EVEROLD LONG TERM FOLLOW-UP

Long-term Evaluation of the Value of Using an MTor Inhibitor (everolimus) for the Minimisation of Anticalceurins in Old-for-old Kidney Transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06504225

Acronym

EVEROLD FUP

Enrollment

260

Registered

2024-07-16

Start date

2024-08-23

Completion date

2025-08-01

Last updated

2025-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplant; Complication, Failure

Brief summary

Long Term Follow up of EVEROLD study

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Informed patients participating to the EVEROLD study * Patient having completed the EVEROLD M12 follow-up visit * Patient agreeing to participate in the observational study

Exclusion criteria

* Opposition to the use his medical data * Patient under legal protection

Design outcomes

Primary

Measure	Time frame	Description
Patient survival	up to 12 years	Patient survival at last follow-up
Graft survival	up to 12 years	Graft survival at last follow-up

Secondary

Measure	Time frame	Description
Major cardiovascular events	up to 12 years	—
Cancer rate	up to 12 years	Skin cancer, solid organ tumor and hematological cancer
Rejection rate	up to 12 years	Biopsy proven rejection
eGFR	up to 12 years	estimated GFR (MDRD and CKD-EPI)
Hospitalization	up to 12 years	Number of hospitalization, hospital stay, reason for hospitalization
Infection rate	up to 12 years	All infections requiring hospitalization

Countries

France

Contacts

Primary ContactYannick Le Meur

yannick.lemeur@chu-brest.fr+330298347014

Backup ContactChristelle RATAJCZAK

christelle.ratajczak@chu-brest.fr+330298347061

Outcome results